Research graph
References from Telmisartan alters the transcriptomes of cancer associated fibroblasts and fibrocytes in a solid tumour model. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/nrc.2016.73
10.1038/nrc.2016.73 · External reference
10.1016/j.bcp.2013.01.018
10.1016/j.bcp.2013.01.018 · External reference
10.1038/nm.1908
10.1038/nm.1908 · External reference
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
10.1093/jnci/djx121 · 2018 · External reference
10.1038/s41388-021-01870-x
10.1038/s41388-021-01870-x · External reference
Fibrocytes in the Tumor Microenvironment
10.1007/978-3-030-35723-8_6 · 2020 · External reference
10.1038/s41467-022-33458-8
10.1038/s41467-022-33458-8 · External reference
10.1084/jem.20162024
10.1084/jem.20162024 · External reference
10.1158/1078-0432.ccr-18-1955
10.1158/1078-0432.ccr-18-1955 · External reference
Tracking the elusive fibrocyte: Identification and characterization of collagen producing hematopoietic lineage cells during murine wound healing
10.1002/stem.1648 · 2014 · External reference
10.1038/s41467-024-45766-2
10.1038/s41467-024-45766-2 · External reference
10.1158/0008-5472.can-22-1427
10.1158/0008-5472.can-22-1427 · External reference
10.3389/fmolb.2024.1343523
10.3389/fmolb.2024.1343523 · External reference
10.1038/ncomms.3516
10.1038/ncomms.3516 · External reference
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
10.1001/jamaoncol.2019.0892 · 2019 · External reference
Telmisartan: a different angiotensin II receptor blocker protecting a different population?
10.1177/147323000903700602 · 2009 · External reference
10.1016/j.canlet.2020.07.015
10.1016/j.canlet.2020.07.015 · External reference
Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy
10.1111/cas.16385 · 2025 · External reference
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
10.1038/s43018-023-00614-y · 2023 · External reference
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
10.3390/ijms23105533 · 2022 · External reference
PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
10.1182/blood-2023-181383 · 2023 · External reference
10.1038/s41467-023-40850-5
10.1038/s41467-023-40850-5 · External reference
10.1158/2326-6066.cir-13-0027
10.1158/2326-6066.cir-13-0027 · External reference
10.18632/oncotarget.8098
10.18632/oncotarget.8098 · External reference
10.1038/onc.2012.460
10.1038/onc.2012.460 · External reference
10.1371/journal.pone.0090353
10.1371/journal.pone.0090353 · External reference
10.1007/s00280-017-3245-5
10.1007/s00280-017-3245-5 · External reference
10.1093/jnci/dju169
10.1093/jnci/dju169 · External reference
10.1177/0192623311416259
10.1177/0192623311416259 · External reference
A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
10.1200/jco.2016.34.15_suppl.4070 · 2016 · External reference
A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC)
10.1200/jco.2016.34.15_suppl.4019 · 2016 · External reference
10.1007/s12012-014-9297-4
10.1007/s12012-014-9297-4 · External reference
10.1158/1078-0432.ccr-14-1380
10.1158/1078-0432.ccr-14-1380 · External reference
10.1097/md.0000000000006394
10.1097/md.0000000000006394 · External reference
10.1593/tlo.13346
10.1593/tlo.13346 · External reference
10.1002/cncr.30079
10.1002/cncr.30079 · External reference
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors
10.1016/j.clgc.2022.04.012 · 2022 · External reference
Investigating Survival Associated with Angiotensin Blockade Agents in Patients with Pancreatic Cancer
10.1016/j.jval.2014.03.418 · 2014 · External reference
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients
10.1007/s00432-014-1873-2 · 2015 · External reference
10.7717/peerj.8188
10.7717/peerj.8188 · External reference
10.1093/jnci/djaf056
10.1093/jnci/djaf056 · External reference
Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers
2005 · External reference
10.1124/pr.112.007278
10.1124/pr.112.007278 · External reference
Telmisartan augments DNA damage and tumor immunogenicity to improve cancer treatments
2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/s41587-023-01767-y
10.1038/s41587-023-01767-y · External reference
Unresolved reference
External reference
DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors
10.1016/j.cels.2019.03.003 · 2019 · External reference
10.32614/cran.package.data.table
10.32614/cran.package.data.table · External reference
Unresolved reference
External reference
10.32614/cran.package.magrittr
10.32614/cran.package.magrittr · External reference
10.32614/cran.package.qs
10.32614/cran.package.qs · External reference
Unresolved reference
External reference
Welcome to the Tidyverse
10.21105/joss.01686 · 2019 · External reference
10.1007/978-3-319-24277-4_9
10.1007/978-3-319-24277-4_9 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.32614/cran.package.viridis
10.32614/cran.package.viridis · External reference
Unresolved reference
External reference
10.1007/0-387-29362-0_15
10.1007/0-387-29362-0_15 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/s41590-018-0276-y
10.1038/s41590-018-0276-y · External reference
10.1101/060012
10.1101/060012 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/nbt.2859
10.1038/nbt.2859 · External reference
10.1038/nmeth.4150
10.1038/nmeth.4150 · External reference
10.1038/nmeth.4402
10.1038/nmeth.4402 · External reference
10.1038/s41586-019-0969-x
10.1038/s41586-019-0969-x · External reference
Unresolved reference
External reference
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
10.1001/jamaoncol.2019.0892 · ExternalCitation · doi-reference
10.1002/cncr.30079
10.1002/cncr.30079 · ExternalCitation · doi-reference
Tracking the elusive fibrocyte: Identification and characterization of collagen producing hematopoietic lineage cells during murine wound healing
10.1002/stem.1648 · ExternalCitation · doi-reference
10.1007/0-387-29362-0_15
10.1007/0-387-29362-0_15 · ExternalCitation · doi-reference
Fibrocytes in the Tumor Microenvironment
10.1007/978-3-030-35723-8_6 · ExternalCitation · doi-reference
10.1007/978-3-319-24277-4_9
10.1007/978-3-319-24277-4_9 · ExternalCitation · doi-reference
10.1007/s00280-017-3245-5
10.1007/s00280-017-3245-5 · ExternalCitation · doi-reference
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients
10.1007/s00432-014-1873-2 · ExternalCitation · doi-reference
10.1007/s12012-014-9297-4
10.1007/s12012-014-9297-4 · ExternalCitation · doi-reference
10.1016/j.bcp.2013.01.018
10.1016/j.bcp.2013.01.018 · ExternalCitation · doi-reference
10.1016/j.canlet.2020.07.015
10.1016/j.canlet.2020.07.015 · ExternalCitation · doi-reference
DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors
10.1016/j.cels.2019.03.003 · ExternalCitation · doi-reference
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors
10.1016/j.clgc.2022.04.012 · ExternalCitation · doi-reference
Investigating Survival Associated with Angiotensin Blockade Agents in Patients with Pancreatic Cancer
10.1016/j.jval.2014.03.418 · ExternalCitation · doi-reference
10.1038/nbt.2859
10.1038/nbt.2859 · ExternalCitation · doi-reference
10.1038/ncomms.3516
10.1038/ncomms.3516 · ExternalCitation · doi-reference
10.1038/nm.1908
10.1038/nm.1908 · ExternalCitation · doi-reference
10.1038/nmeth.4150
10.1038/nmeth.4150 · ExternalCitation · doi-reference
10.1038/nmeth.4402
10.1038/nmeth.4402 · ExternalCitation · doi-reference
10.1038/nrc.2016.73
10.1038/nrc.2016.73 · ExternalCitation · doi-reference
10.1038/onc.2012.460
10.1038/onc.2012.460 · ExternalCitation · doi-reference
10.1038/s41388-021-01870-x
10.1038/s41388-021-01870-x · ExternalCitation · doi-reference
10.1038/s41467-022-33458-8
10.1038/s41467-022-33458-8 · ExternalCitation · doi-reference
10.1038/s41467-023-40850-5
10.1038/s41467-023-40850-5 · ExternalCitation · doi-reference
10.1038/s41467-024-45766-2
10.1038/s41467-024-45766-2 · ExternalCitation · doi-reference
10.1038/s41586-019-0969-x
10.1038/s41586-019-0969-x · ExternalCitation · doi-reference
10.1038/s41587-023-01767-y
10.1038/s41587-023-01767-y · ExternalCitation · doi-reference
10.1038/s41590-018-0276-y
10.1038/s41590-018-0276-y · ExternalCitation · doi-reference
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
10.1038/s43018-023-00614-y · ExternalCitation · doi-reference
10.1084/jem.20162024
10.1084/jem.20162024 · ExternalCitation · doi-reference
10.1093/jnci/djaf056
10.1093/jnci/djaf056 · ExternalCitation · doi-reference
10.1093/jnci/dju169
10.1093/jnci/dju169 · ExternalCitation · doi-reference
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
10.1093/jnci/djx121 · ExternalCitation · doi-reference
10.1097/md.0000000000006394
10.1097/md.0000000000006394 · ExternalCitation · doi-reference
10.1101/060012
10.1101/060012 · ExternalCitation · doi-reference
Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy
10.1111/cas.16385 · ExternalCitation · doi-reference
10.1124/pr.112.007278
10.1124/pr.112.007278 · ExternalCitation · doi-reference
10.1158/0008-5472.can-22-1427
10.1158/0008-5472.can-22-1427 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-14-1380
10.1158/1078-0432.ccr-14-1380 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-18-1955
10.1158/1078-0432.ccr-18-1955 · ExternalCitation · doi-reference
10.1158/2326-6066.cir-13-0027
10.1158/2326-6066.cir-13-0027 · ExternalCitation · doi-reference
10.1177/0192623311416259
10.1177/0192623311416259 · ExternalCitation · doi-reference
Telmisartan: a different angiotensin II receptor blocker protecting a different population?
10.1177/147323000903700602 · ExternalCitation · doi-reference
PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
10.1182/blood-2023-181383 · ExternalCitation · doi-reference
A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC)
10.1200/jco.2016.34.15_suppl.4019 · ExternalCitation · doi-reference
A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
10.1200/jco.2016.34.15_suppl.4070 · ExternalCitation · doi-reference
10.1371/journal.pone.0090353
10.1371/journal.pone.0090353 · ExternalCitation · doi-reference
10.1593/tlo.13346
10.1593/tlo.13346 · ExternalCitation · doi-reference
10.18632/oncotarget.8098
10.18632/oncotarget.8098 · ExternalCitation · doi-reference
Welcome to the Tidyverse
10.21105/joss.01686 · ExternalCitation · doi-reference
10.32614/cran.package.data.table
10.32614/cran.package.data.table · ExternalCitation · doi-reference
10.32614/cran.package.magrittr
10.32614/cran.package.magrittr · ExternalCitation · doi-reference
10.32614/cran.package.qs
10.32614/cran.package.qs · ExternalCitation · doi-reference
10.32614/cran.package.viridis
10.32614/cran.package.viridis · ExternalCitation · doi-reference
10.3389/fmolb.2024.1343523
10.3389/fmolb.2024.1343523 · ExternalCitation · doi-reference
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
10.3390/ijms23105533 · ExternalCitation · doi-reference
10.7717/peerj.8188
10.7717/peerj.8188 · ExternalCitation · doi-reference
